Horiguchi Jun, Rai Yoshiaki, Tamura Kazuo, Taki Toshihiko, Hisamatsu Kazufumi, Ito Yoshinori, Seriu Taku, Tajima Tomoo
Breast and Endocrine Surgery, Gunma University Hospital, 3-39-15 Showa-Machi, Maebashi, Gunma 371-8511, Japan.
Anticancer Res. 2009 Feb;29(2):625-30.
The efficacy and safety of weekly paclitaxel was evaluated in Japanese women with advanced or metastatic breast cancer.
Paclitaxel was given by single weekly intravenous infusion at 100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of a 49-day cycle to women with advanced or metastatic breast cancer not responding to other chemotherapy.
A total of 69 enrolled patients received a median of 3 (range 1-13) cycles of treatment. The overall response rate was 44.9%, comprising 3 complete responses (CRs) and 28 partial responses (PRs). Median durations of CR and PR were 64.0 (range 57-499) and 113.0 (range 29-590) days, respectively. Grade 3 or greater adverse reactions included neutropenia in 37.7%, leukopenia in 31.9% and neuropathy in 5.8%.
A weekly regimen of paclitaxel was well tolerated and achieved a relatively high response rate in Japanese breast cancer patients with advanced or metastatic disease.
对日本晚期或转移性乳腺癌女性患者评估了每周一次紫杉醇的疗效和安全性。
对于对其他化疗无反应的晚期或转移性乳腺癌女性患者，在49天周期的第1、8、15、22、29和36天，每周单次静脉输注紫杉醇，剂量为100mg/m²。
总共69名入组患者接受了中位数为3（范围1 - 13）个周期的治疗。总缓解率为44.9%，包括3例完全缓解（CR）和28例部分缓解（PR）。CR和PR的中位持续时间分别为64.0（范围57 - 499）天和113.0（范围29 - 590）天。3级或更高级别的不良反应包括37.7%的中性粒细胞减少、31.9%的白细胞减少和5.8%的神经病变。
每周一次紫杉醇方案在日本晚期或转移性乳腺癌患者中耐受性良好，并取得了相对较高的缓解率。
Zotero 插件